Company / Financials
GOLDENWELL BIOTECH, INC. Financials
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$139
FY2024 · -92.4% YoY
Net Income
-$131.5K
FY2024 · -12.0% YoY
Profit Margin
-94602.9%
FY2024 · net income / revenue
ROE
-
FY2024 · return on equity
Total Assets
$224.2K
FY2024
Total Debt
$174.0K
-3.68x debt/equity
Equity
-$47.2K
FY2024
ROA
-58.7%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -6.92 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$139-92.4% YoYNet Income HistoryProfit after all expenses and taxes-$131.5K-12.0% YoYGross Profit HistoryRevenue minus cost of goods sold$64-90.4% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$75-93.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$123.1K-6.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$123.2K+5.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$8.4K+447.2% YoYIncome Tax HistoryTotal income tax expense$0EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$0.00Shares Outstanding HistoryWeighted average diluted shares outstanding99.0M0.0% YoY